biomarker-trends-header.png

23andMe Case Highlights Regulatory Ambiguity

FDA's warnings to 23andMe illustrate some of the major problems with current regulation of diagnostic tests.

   

December

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report